| Assessing the impact of protocol design changes on clinical trial performance | American Journal of Therapeutics | 2008 | 102 |
| Switching prescription drugs to over the counter | BMJ, The | 2005 | 51 |
| Clinical and economic challenges facing pharmacogenomics | Pharmacogenomics Journal | 2013 | 45 |
| A Study on the Application and Use of Artificial Intelligence to Support Drug Development | Clinical Therapeutics | 2019 | 37 |
| Global Public Attitudes About Clinical Research and Patient Experiences With Clinical Trials | JAMA Network Open | 2018 | 36 |
| Complementary versus companion diagnostics: apples and oranges? | Biomarkers in Medicine | 2015 | 30 |
| Comparing patient access to pharmaceuticals in the UK and US | Applied Health Economics and Health Policy | 2006 | 30 |
| The evolution of biotechnology and its impact on health care | Health Affairs | 2015 | 26 |
| Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug Administration | Oncologist | 2013 | 26 |
| Public- and Private-Sector Contributions to the Research and Development of the Most Transformational Drugs in the Past 25 Years: From Theory to Therapy | Therapeutic Innovation and Regulatory Science | 2016 | 26 |
| A Survey of Adverse Event Reporting Practices Among US Healthcare Professionals | Drug Safety | 2016 | 25 |
| Personalized Medicine's Bottleneck: Diagnostic Test Evidence and Reimbursement | Journal of Personalized Medicine | 2014 | 24 |
| Mapping the Landscape of Patient-centric Activities Within Clinical Research | Clinical Therapeutics | 2017 | 22 |
| Variability in Protocol Design Complexity by Phase and Therapeutic Area | Drug Information Journal | 2011 | 19 |
| Measuring the Impact of Patient Engagement and Patient Centricity in Clinical Research and Development | Therapeutic Innovation and Regulatory Science | 2020 | 17 |
| The pediatric studies initiative: after 15 years have we reached the limits of the law? | Clinical Therapeutics | 2014 | 17 |
| New Benchmarks Characterizing Growth in Protocol Design Complexity | Therapeutic Innovation and Regulatory Science | 2018 | 16 |
| Landscape of Innovation for Cardiovascular Pharmaceuticals: From Basic Science to New Molecular Entities | Clinical Therapeutics | 2017 | 15 |
| Establishing Return-on-Investment Expectations for Patient-Centric Initiatives | Therapeutic Innovation and Regulatory Science | 2015 | 13 |
| Prospects for rapid advances in the development of new medicines for special medical needs | Clinical Pharmacology and Therapeutics | 2014 | 13 |
| The biotechnology innovation machine: a source of intelligent biopharmaceuticals for the pharma industry--mapping biotechnology's success | Clinical Pharmacology and Therapeutics | 2014 | 12 |
| Translational research and the evolving landscape for biomedical innovation | Journal of Investigative Medicine | 2012 | 12 |
| Reflections on the Evolution of Patient Engagement in Drug Development | Pharmaceutical Medicine | 2019 | 11 |
| Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial | Clinical Infectious Diseases | 2018 | 11 |
| Evaluating the Completeness of ClinicalTrials.gov | Therapeutic Innovation and Regulatory Science | 2019 | 11 |
